Athenex Stock

Athenex Current Liabilities

Delisted

The Current Liabilities of Athenex (ATNX) as of Aug 23, 2026 is 182.06 M USD. In the previous year, Current Liabilities was 161.90 M USD — a change of 12.45% (higher).

Current Liabilities

182.06 MUSD

YoY

12.45%

Last updated:

Current Liabilities of Athenex is 2026 182.06 M USD. Current Liabilities of Athenex was 2025 161.90 M USD. It decreases by 12.45% higher compared to the previous year.

The Athenex Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2015
22.83 M USD
Jan 1, 2016
48.38 M USD
Jan 1, 2017
70.84 M USD
Jan 1, 2018
89.99 M USD
Jan 1, 2019
119.11 M USD
Jan 1, 2020
101.37 M USD
Jan 1, 2021
161.90 M USD
Jan 1, 2022
182.06 M USD
The Athenex Current Liabilities history
YEARCurrent LiabilitiesYoY
182.06 MUSD+12.45%
161.90 MUSD+59.72%
101.37 MUSD-14.90%
119.11 MUSD+32.37%
89.99 MUSD+27.03%
70.84 MUSD+46.42%
48.38 MUSD+111.94%
22.83 MUSD+165.13%
8.61 MUSD
Access this data via the Eulerpool API

Athenex Stock analysis

What does Athenex do? Athenex Inc was founded in 2003 and is headquartered in Buffalo, New York. The company specializes in the development and marketing of innovative drugs and therapies for the treatment of cancer and other serious diseases. Athenex's business model is based on collaboration with other companies and research institutions. The company works closely with academic partners to identify and develop new technologies and active ingredients. Athenex has also entered into several collaboration agreements with major pharmaceutical companies to facilitate the marketing of its products. The company has multiple divisions: Athenex Pharmaceutical Division, Athenex Oncology Division, and Athenex Pharmaceutical Technology Division. The Athenex Pharmaceutical Division focuses on the development and marketing of drugs for the treatment of cancer and other serious illnesses. The company has several promising drug candidates in its pipeline, including Oratopo, a drug for the treatment of breast cancer, and KX-2-391, a drug for the treatment of prostate cancer. The Athenex Oncology Division focuses on the development and marketing of innovative cancer treatment methods. The company has several promising therapy approaches in its pipeline, including an immunological cancer treatment based on activating the immune system to fight cancer cells. The Athenex Pharmaceutical Technology Division utilizes advanced technologies to improve the effectiveness and tolerability of drugs, including novel drug delivery systems and innovative packaging forms. Athenex also offers a wide range of products and services for the pharmaceutical industry, including drug development and manufacturing, as well as the supply of active ingredients and excipients. Overall, Athenex has a broad and interesting business model and a promising portfolio of drug candidates and therapy approaches in its pipeline. The company has also established strong partnerships with other companies and research institutions to advance its development and marketing of drugs and therapies. Athenex is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Athenex stock

Current Liabilities of Athenex is 182.06 M USD in 2026.

Current Liabilities of Athenex changed from 161.90 M USD to 182.06 M USD, representing a 12.45% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Athenex since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Athenex historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Athenex

All Key Metrics — Athenex